XORTX (NASDAQ: XRTX) shareholders approve board slate and consolidation

Rhea-AI Filing Summary

XORTX Therapeutics Inc. reported the results of its annual and special shareholder meeting held on March 24, 2026. Shareholders representing 2,407,148 common shares, approximately 35% of the shares outstanding, were present.

All items on the agenda were approved, including the election of five management nominees to the board, re-appointment of Davidson & Company LLP as auditors with directors authorized to set their pay, re-approval of the stock option plan and approval of a share consolidation.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-40858

XORTX Therapeutics Inc.

3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		XORTX Therapeutics Inc.
		(Registrant)
Date: March 26, 2026		By:	/s/ Allen Davidoff
		Name:	Allen Davidoff
		Title:	Chief Executive Officer

EXHIBIT INDEX

99.1 News release dated March 26, 2026

 

EXHIBIT 99.1

XORTX Announces Results of  Annual and Special Meeting of Shareholders

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Tuesday, March 24, 2026.

A total of 2,407,148 common shares of the Company were represented at the Meeting, representing approximately 35% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including election of all five management nominees (Anthony Giovinazzo (Chair), Allen Davidoff (CEO), Mika Grasso, Richard Grieve and George Scorsis) to the board of directors of the Company, the appointment of Davidson & Company LLP as auditors of the Company for the ensuing year and authorization of the directors to fix their remuneration, re-approval of the stock option plan and approval of the share consolidation. Detailed results are available in the Report of Voting Results filed on the Company’s SEDAR+ profile at www.sedarplus.ca.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.
For more information, please contact:

Allen Davidoff, CEO		Nick Rigopulos, Director of Communications
adavidoff@xortx.com		nick@alpineequityadv.com
+1 403 455 7727		+1 617 901 0785

Forward Looking Statements

This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, regulatory approvals, such as the TSXV; the ability to complete the Consolidation; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.

FAQ

What did XORTX (XRTX) announce in its March 2026 Form 6-K?

XORTX announced the results of its March 24, 2026 annual and special shareholder meeting. All matters, including director elections, auditor appointment, stock option plan re-approval and a share consolidation, were approved by the shareholders present.

How many XORTX (XRTX) shares were represented at the March 24, 2026 meeting?

A total of 2,407,148 XORTX common shares were represented at the March 24, 2026 meeting, accounting for approximately 35% of the company’s issued and outstanding common shares at the time of the meeting.

Which directors were elected at XORTX’s March 2026 shareholder meeting?

Shareholders elected all five management nominees to XORTX’s board: Anthony Giovinazzo (Chair), Allen Davidoff (CEO), Mika Grasso, Richard Grieve and George Scorsis. Each nominee was approved as a director for the ensuing period.

Which auditor did XORTX (XRTX) shareholders approve for the ensuing year?

Shareholders approved Davidson & Company LLP as XORTX’s auditors for the ensuing year. They also authorized the company’s directors to fix the auditors’ remuneration for their services during the upcoming audit period.

Did XORTX shareholders approve a stock option plan and share consolidation?

Yes. Shareholders re-approved XORTX’s stock option plan and also approved a share consolidation. These items were among several matters presented at the March 24, 2026 annual and special meeting and were duly authorized.

What business is XORTX Therapeutics (XRTX) focused on?

XORTX is a late-stage clinical pharmaceutical company developing therapies targeting gout and progressive kidney disease. Its programs include XRx-026 for gout, XRx-008 for ADPKD, XRx-101 for acute kidney injury, and XRx-225 for Type 2 diabetic nephropathy.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 6.1 KB